MALVERN, Pa.--(BUSINESS WIRE)--Protez Pharmaceuticals, a privately held biopharmaceutical company focused on the development of innovative antibiotics to combat drug resistant and life threatening infections, today announced the commencement of a Phase II clinical study of the company’s lead compound, PZ-601, in patients with complicated skin and skin structure infections. PZ-601 is a new, injectable antibiotic with a uniquely broad spectrum of activity against drug-resistant Gram positive pathogens including MRSA and Gram negative bacteria.
